1-2 of 2
Bruyère Mahuzier, Pharm D
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Safety Analysis of Ruxolitinib (RUX) Vs Best Available Therapy (BAT) in Patients (pts) with Steroid-Refractory (SR) Acute Graft-Vs-Host Disease (aGVHD) in the Randomized Phase 3 REACH2 Study

Nikolas Von Bubnoff, Jason P Butler, MBBS, MMedSc, FRACP, FRCPA, Eva Maria Wagner, MD, Edouard Forcade, MD PhD, Jaime Sanz Caballer, MD PhD, Domenico Russo, MD, Giovanni Grillo, MD, Tsila Zuckerman, MD, Sinem Civriz Bozdag, MD, Francis A. Ayuk, Friedrich Stoelzel, PD, MD, Sung-Soo Yoon, MD PhD, Jose Valentín García Gutiérrez, MD PhD, David Ritchie, MD ChB, PhD FRACP, FRCPA, Claude-Eric Bulabois, MD, Marie Thérèse Rubio, MD PhD, Judith Xu, Juliane Morando, MD, Bruyère Mahuzier, Pharm D, Satish Mahadevaiah Chandraiah, Gérard Socié, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 40–42.
https://doi.org/10.1182/blood-2020-137603
Published: 2020
Journal Articles

Efficacy and Safety of Ruxolitinib in Regularly Transfused Patients with Thalassemia: Results from Single-Arm, Multicenter, Phase 2a Truth Study

Yesim Aydinok, MD, Zeynep Karakas, MD, Elena Cassinerio, MD, Noppadol Siritanaratkul, MD, Antonis Kattamis, MD, Aurelio Maggio, MD, Norbert Hollaender, PhD, Bruyère Mahuzier, Pharm D, Brian Gadbaw, MD, Ali T. Taher, MD PhD
Journal: Blood
Blood (2016) 128 (22): 852.
https://doi.org/10.1182/blood.V128.22.852.852
Published: 2016